Gaithersburg based Novavax has announced that its 2023-2024 protein-based non-mRNA COVID vaccine has received Emergency Use Authorization from the FDA and will soon be available in pharmacies nationwide. Novavax’s Silvia Taylor will be joining Montgomery County Executive Marc Elrich today at noon for a media briefing. Per Novavax:
“Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older. Immediately upon authorization, Novavax’s vaccine has also been included in the recommendations issued by the U.S. Centers for Disease Control and Prevention (CDC) on September 12, 2023.